Skip to main
ALLO

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics Inc. demonstrates a promising outlook due to its innovative pipeline, particularly with the potential for cema-cel to achieve a 25-30% improvement in minimal residual disease (MRD) conversion in the upcoming futility analysis, which could significantly enhance stock valuation. Additionally, the company has a robust financial position with $258 million in cash, providing a runway until the first quarter of 2028, which enables continued development of its core programs in cancer and autoimmune diseases. Recent analyses, such as the ZUMA-7 study, underscore the increasing relevance of MRD negativity in improving event-free survival, indicating that successful outcomes in ongoing trials could yield substantial benefits for the company's future performance.

Bears say

Allogene Therapeutics Inc faces significant risks stemming from potential failures in its clinical trials, particularly with key products like UCART19, which could negatively affect investor confidence across its entire platform. The company is also confronting considerable competition in the immuno-oncology landscape, which may dilute market share for its therapies. Additionally, persistent net losses, as evidenced by a $38.8 million loss in the latest quarter, underscore the financial instability, while challenges related to manufacturing quality control may hinder product launch timelines and operational scalability.

ALLO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 9 analysts, ALLO has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.